KRAS and colorectal carcinoma: Because the increase in β-catenin, RAS, and EGFR levels in CRC contributes to synergistically promote cell growth and transformation, we tested the effects of KYA1797K on the growth of CRC cells, especially cells resistant to cetuximab, due to KRAS mutations.